Search

everythinglearnresearchcommunity

for

Search:↓

ATIR101 improves survival in stem cell transplant patients; Australian stem cell treatment decisions are influenced by regulation changes.

Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.

Baricitinib-loaded EVs help hair regrowth in alopecia areata by reducing inflammation and promoting hair follicle regeneration.

Tofacitinib helped regrow hair in a patient with severe hair loss and improved their quality of life without side effects.

Blocking IL-12/IL-23 does not help with hair loss in alopecia areata for mice or humans.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Tofacitinib effectively treated both ulcerative colitis and alopecia areata in two patients.

Combining imiquimod with diphenylcyclopropenone may improve treatment outcomes for alopecia areata patients who don't respond to diphenylcyclopropenone alone.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Oral tofacitinib successfully treated a girl's severe skin and hair conditions.

Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Alternative treatments are needed when Tofacitinib alone fails for alopecia areata.

Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

The FDA approved a new Pfizer drug for hair loss in teens.

Upadacitinib improves life quality for Alopecia Areata patients without worsening skin issues.

JAK inhibitors are effective treatments for alopecia areata.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

A patient with PPP had rare skin reactions to adalimumab, which improved after stopping smoking and continuing acitretin.

Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.

Long-term data and a team approach are needed to manage chronic side effects from cancer treatments.

Ritlecitinib improves hair regrowth satisfaction in alopecia areata patients.

Baricitinib is effective and safe for treating alopecia areata in Korea.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

All parts of the CLASI-A score are important for assessing skin activity in cutaneous lupus erythematosus.

An automated system can predict death risk in thin melanoma by analyzing immune cells.

Apremilast may help treat lichen planopilaris and frontal fibrosing alopecia when other treatments fail.